A B S T R A C T Inhibition of thyrotropin (TSH) release by chronic treatment with small quantities of triiodothyronine (Ts) and thyroxine (T4) was evaluated by determining the serum TSH response to thyrotropin-releasing hormone (TRH) in normal subjects and hypothyroid patients. Response to TRH was determined before treatment and after each dosage of a synthetic combination of Ts + T4 had been given for 3-4 wk.
INTRODUCTION
The objective of this study was to quantitate the degree to which small quantities of triiodothyronine (Ts)1 and thyroxine (T4) can inhibit the release of thyrotropin (TSH) in man. Although the ability of exogenous Ts and T4 to reduce the elevated serum TSH levels in patients with primary hypothyroidism to within the normal range has been well documented (1, 2) , determination of the quantity of T3 and/or T4 necessary to suppress serum TSH from normal to below normal levels had been difficult previously because of the inability to distinguish between normal and low serum TSH levels by the TSH immunoassay.
The recent availability of synthetic thyrotropin-releasing hormone (TRH), which stimulates TSH release in normal man (3) (4) (5) , makes possible the determination of the quantity of Ts and/or To necessary to inhibit TSH release to a greater extent than it is inhibited normally; greater than normal inhibition should be manifest, presumably, by a subnormal serum TSH response to exogenous TRH. It already has been demonstrated, in fact,, that in overt hyperthyroidism TSH release is inhibited to the extent that the administration of TRH in usually effective doses produces virtually no rise in serum TSH (6, 7) . The inhibitory effect of smaller elevations of serum T3 and To levels on TSH release was determined in the present study by measuring the serum TSH response to the acute i.v. administration of TRH to normal subjects and patients with primary hypothyroidism who were treated chronically with small dosages of a synthetic combination of T8 + T4. Concomitant measurement of serum Ts and T4 levels at the time of the TRH tests demonstrated the serum levels of these hormones necessary to produce inhibition of the TSH response to TRH. 1Abbreviations used in this paper: PBI, protein-bound iodine; Ts, triiodothyronine; T4, thyroxine, TRH, thyrotropin-releasing hormone; TSH, thyrotropin. (8) . Before the injection of TRH blood was drawn for the determination of serum Ts and T4 concentrations, as well as for the determination of serum TSH concentration.
The standard TRH dose was 400 lg, since this is the minimum dose that produces the maximum TSH response in normal subjects (8) . The normal subjects, after the initial TRH test, took 15 + 60 daily for 3-4 wk before being tested again with TRH. After the second TRH test, the subjects took 30+ 120 for 3-4 wk before being tested for a third time. The hypothyroid patients followed the same protocol, except that they took the 22.5 +90 dosage, as well as the other dosages, and had a TRH test on this dosage. Six of the normal subjects were tested with 25 1Ag of TRH, as well as with 400 Ag TRH, while still taking 15 + 60. In these cases the second TRH test was at least 3 days after the first. The T3+ To medication was taken once a day, in the morning, and the TRH tests were always done 24 hr after the last dose at any given dosage. No measurements of either TSH response to TRH or serum Ts or T4 levels were made until each dosage of T, + T4 had been taken for [3] [4] wk, because available evidence suggests that serum TSH levels in primary hypothyroid patients do not equilibrate until thyroid replacement medication has been given for at least that long (2) .
Serum TSH (9) and serum Ts (10) concentrations were measured by immunoassay. The anti-T3 serum used in the Ts immunoassay was different from the one described, and it gave lower serum Ts values. Serum T4 was measured by a competitive protein binding technique (11) . Normal values for these assays in this laboratory are TSH, 2-8 JU/ml; Ts, 70-150 ng/100 ml; and T4, 5-11 I&g/100 ml. All samples for the determination of either TSH, Ts, or T4 from any one subject were analyzed in the same assay run. Statistical significance was determined by the paired t test (12) .
RESULTS
Normal subjects-TSH response. Fig. 1 illustrates the mean serum TSH responses to i.v. TRH in normal subjects before and after chronic treatment with Ts + T4. Table II details the individual baseline TSH levels and maximum incremental TSH increase above the baseline levels (maximum ATSH) in the same subjects. The mean baseline level and the mean maximum ATSH in these young males were similar to those levels previously described for young (2O-39-yr old) males with regard to both the 400 and 25 lsg doses of TRH (8) . Chronic treatment with 15 + 60 resulted in a 76% reduction of the maximum ATSH response to 400 ug TRH and an 87% reduction of the maximum ATSH response to 25 *sg TRH (Table II) . These reductions were statistically significant: P < 0.01 for the 400 ig TRH test, P < 0.05 for the 25 lyg TRH test. Six of the eight subjects, moreover, had maximum ATSH responses (Table II) to 400 sAg TRH that were below the normal range for 20-39-yr old males (8) .
Chronic treatment of these normal subjects with 30 + 120 virtually abolished the mean serum TSH response to 400 usg TRH ( Fig. 1) , principally by suppressing the responses of the two subjects, J. M. and D. O., whose TSH responses had not been suppressed as much by the 15 + 60 treatment as had those of the other six subjects (Table II) .
Normal subjects-Ts and T4 levels. Normal subjects-Ta and T4 levels during a 24 hr period. To determine if the serum concentrations of Ts and T4 just before the TRH test, i.e. 24 hr after the last daily dose of Ts +T4, reflected accurately the serum levels at all times during the previous 24 hr, six additional normal subjects, aged 20-39, also were given T, + T4. Serum T3 and To levels were determined at frequent intervals during 24-hr periods before beginning medication, at the end of 3-4 wk of taking 15 + 60 once each day, and at the end of 3-4 wk of taking 30 + 120 once each day (Fig. 2) . No significant diurnal variation in either serum T3 or T4 levels was found before treatment. At the end of 3-4 wk of taking 15 + 60 each day, the mean serum T3 level in the six subjects immediately before taking the last dose of 15 + 60 (zero time) was 103±8 ng/100 ml, not significantly different from that before treatment. The administration of the last dose of 15 + 60 produced a detectable rise in the serum Ti level.
The peak rise, to 163+10 ng/100 ml, occurred 2 hr after the ingestion of the dose and was significantly (P < 0.01) greater than the zero time that day. Serum To levels were not affected, either at zero time or after ingestion of the last dose of 15 + 60.
At the end of 3-4 wk of taking 30 + 120 each day, the mean serum Ts level at zero time was 148±8 ng/100 ml, significantly greater (P <0.01) than before treatment.
The administration of the last dose of 30 + 120 produced an even greater rise in the serum Ts levels. The peak rise, to 308±18 ng/100 ml, again occurred 2 hr after the ingestion of the dose and was also significantly (P < 0.001) greater than the zero time that day. At this dosage of T3 + T4 the serum T4 level at zero time was 7.6±0.3 isg/lOO ml, not significantly greater than the pretreatment level, 6.9 Iug/lOO ml. The administration of the last dose of 30 + 120 produced a rise in serum T4 level, which reached a plateau at 8.1 to 8.3 ILg/100 ml between 2 and 8 hr after ingestion of the dose and, compared with the zero time that day, was of greater statistical significance (P <0.01) at 6 and 8 hr. Even the peak serum T4 levels, however, were well within the normal range.
Because the serum Ta levels fluctuated significantly in the 24 hr after the ingestion of a dose of Ts + T4, the average Ts level during the 24 hr was calculated for each subject. The calculation was made using the area under each subject's 24-hr Ts response curve, as determined by planimetry. eraged serum T3 levels in the six subjects. The mean averaged pretreatment level, 98±7 ng/100 ml, is well within the normal range. The mean averaged serum T3 level in these six subjects while they were taking 15 + 60 was 129±410 ng/100 ml, which is also well within the normal range, although significantly (P<0.01) higher than the pretreatment level. The mean averaged serum T3 level in these six subjects while they were taking 30 + 120 was 181±7 ng/ml, which is not only significantly higher (P <0.001) than the pretreatment level in the same subjects, but is also above the normal range. The means of the averaged 24-hr serum T4 levels were 6.5±0.5 4lg/100 ml before treatment, 6.5±0.4 ug/100 ml Fig. 4 . This figure shows the responses of the six subjects who received all three Ts + To dosages. The hatched area accompanying each patient's responses represents the normal range of TSH response for a person of that age and sex (8, 13) . What was variable about the responses during treatment with the two smaller T3 + To dosages is that during treatment with 15 + 60 four patients had responses greater than the normal range ("hypothyroid") and two had responses within the normal range ("euthyroid"), while during treatment with 22.5 + 90 three patients had responses greater than in normal and three less than normal ("hyperthyroid"). What was quite consistent about the responses in all six patients was that for each patient there was one 7.5 + 30 increase in dosage which abruptly converted a maximum ATSH that was greater than, or at the upper limit of, normal to one that was subnormal. This abrupt change occurred when the dosage was increased from 15 + 60 to 22.5 + 90 in patients M. B., M. C., and E. R. and when the dosage increased from 22. No studies have been previously reported on the effect of dosages of T3 + To as small as those employed here on TRH-induced TSH release. In one related study (14) a single dose of 100 Ag Ts was given 6 or 18 hr before the TRH test. Although six of the eight subjects had a TSH response, the responses are difficult to interpret, because no control TRH tests were done before the administration of the T3. TSH response to TRH has been tested also in overt hyperthyroidism and found to be markedly subnormal (6, 7). The serum protein-bound iodine (PBI) levels in 19 of the 20 hyperthyroid patients in whom these levels were reported, however, were elevated (7). These elevations contrast to the normal serum T4 levels in the subjects treated with Ts + T4 reported here.
One implication of the data presented here is that the ranges of serum T3 and T4 concentrations in which TSH response to TRH is normal must be very small. Therefore, a replacement dosage of thyroid hormone, one sufficient to maintain a hypothyroid patient in a euthyroid state with a serum TSH level that is not elevated, is generally also a suppressive dosage, capable of suppressing TSH secretion below normal.
Another implication of the data presented here is that the administration of usually effective doses of TRH would not be effective in a patient with an autonomously functioning thyroid gland producing serum T3 and T4 levels higher than his antecedent normal gland did, but not necessarily higher than the normal ranges of serum Ts and T4. This postulated phenomenon may explain why those patients reported by Ormston, Garry, Cryer, and Besser (7) with suspected hyperthyroidism and serum PBI levels in the upper part of the normal range, as well as those with PBI levels above normal, did not have serum TSH responses to TRH.
